Phase I/II trial of DEP cabazitaxel in esophagogastric cancers 

David Pinato, MD, PhD, Imperial College London, London, UK, gives an overview of a Phase I/II trial (2017-003424-76) assessing dendrimer-enhanced (DEP) cabazitaxel in patients with advanced esophagogastric cancers. DEP cabazitaxel had promising antitumor activity and had an encouraging safety profile, where no steroids were needed, which are typical for taxane-based medications. This interview took place at 2024 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Annual Congress in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.